Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nicolas Mouawad

Vascular Surgery West Branch, MI Medical Doctor

NPI 1730388497 CMS profile 697868

2431 S M 30, West Branch, MI 48661

Open in the dashboard

General payments

$1,661,439

2,272 records reported · program years 2019–2025

Research payments

$1,250

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$102,316

5 holdings reported · through program year 2025

Research they led as principal investigator

$886,486 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Nicolas Mouawad of West Branch, MI is reported in the CMS Open Payments database as having received $1,661,439 across 2,272 general payments and $1,250 in research payments paid to them. Separately, studies naming them as principal investigator received $886,486 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $102,316 across 5 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $363,920 433
2025 Research $1,250 2
2024 General $311,198 330
2023 General $256,949 310
2022 General $327,787 447
2021 General $150,300 267
2020 General $129,237 189
2019 General $122,047 296
2025 Ownership $13,087 1
2024 Ownership $13,087 1
2023 Ownership $13,087 1
2022 Ownership $13,087 1
2021 Ownership $49,968 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicolas Mouawad
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Nicolas Mouawad were reported at $363,920. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Nicolas Mouawad Vascular Surgery median Middle half National median
2019 $122,047 $796 $226–$2,363 $163
2020 $129,237 $348 $118–$1,110 $114
2021 $150,300 $471 $158–$1,421 $132
2022 $327,787 $725 $222–$2,183 $149
2023 $256,949 $836 $257–$2,440 $160
2024 $311,198 $909 $252–$2,619 $164
2025 $363,920 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Inari Medical, Inc. $497,395 370 payments
  2. Endologix, Inc. $251,699 406 payments
  3. Shockwave Medical, Inc $195,827 198 payments
  4. Janssen Pharmaceuticals, Inc $116,746 157 payments
  5. MIMEDX Group, Inc. $82,598 34 payments
  6. Stryker Corporation $59,614 44 payments
  7. Boston Scientific Corporation $58,672 82 payments
  8. W. L. Gore & Associates, Inc. $56,152 145 payments
  9. Medtronic, Inc. $52,708 124 payments
  10. Bolton Medical Inc $51,912 99 payments
  11. Other $238,115 613 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $641,408 333 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $601,926 177 payments
  3. Travel and Lodging $203,710 362 payments
  4. Food and Beverage $92,713 1,340 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $75,100 19 payments
  6. Honoraria $25,243 9 payments
  7. Education $21,340 32 payments
Products named General payments · program years 2019–2025
  1. CT THROMBECTOMY SYSTEM KIT $535,307 351 payments
  2. FLOWTRIEVER CATHETER, S $504,858 403 payments
  3. Alto Abdominal Stent Graft System $152,119 218 payments
  4. XARELTO $116,851 158 payments
  5. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Lithoplasty $112,628 128 payments
  6. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Cardiology $78,429 55 payments
  7. AFX $46,045 38 payments
  8. Ovation $43,985 46 payments
  9. ClotTriever $36,363 27 payments
  10. FlowTriever $36,363 27 payments
  11. Other $600,597 1,299 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Veryan Medical Incorporated $1,250 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

202

Median for Vascular Surgery: 122

Drug cost

$29,232

Median for Vascular Surgery: $14,135

Branded share of claims

72.8%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 16 $25,539
Clopidogrel Clopidogrel Bisulfate Brand 131 $2,301
Cilostazol Generic 34 $1,165
Atorvastatin Calcium Generic 21 $228

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 147 billing codes

Paid by Medicare

$253,753

Medicare's payments for the services billed

Medicare patients

962

Average age 74

Services billed

3,075

476 women, 486 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 60%
Arthritis 57%
Diabetes 42%
COPD 38%
Chronic kidney disease 37%
Atrial fibrillation 34%
Heart failure 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
$38 16 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

2,274 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record